Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Apr;43(4):2295-2297.
doi: 10.1007/s10072-022-05898-z. Epub 2022 Jan 20.

SARS-CoV-2 vaccine-related neurological complications

Affiliations
Review

SARS-CoV-2 vaccine-related neurological complications

Nicol G M Oonk et al. Neurol Sci. 2022 Apr.

Abstract

Objective: To describe three cases with neurological symptoms after SARS-CoV-2 vaccination.

Methods: A case series followed by a review of the literature, describing hypotheses on how neurological symptoms might develop after vaccination.

Results: The different temporal relationship between the onset or worsening of different neurological symptoms suggests different pathophysiological mechanisms. Progression of post-infectious myoclonus, caused by a previous SARS-CoV-2-infection, shortly after vaccination suggests a renewed auto-immune mediated crossreaction of antibodies to both viral epitopes and central nervous system components. Thunderclap headache after vaccination suggests a similar pathophysiological mechanism to the headache and other flu-like symptoms described after vaccination against other viruses. This might be ascribed to the activation of immunoinflammatory mediators or accompanying fever. Although headache accompanied by encephalopathy and focal neurological deficit might occur as part of a cytokine release syndrome, this is clinically less likely.

Conclusions: A variety of symptoms, including thunderclap headache, focal deficits and movement disorders, can occur after SARS-CoV-2 vaccination, and an activation or reactivation of the immune system is suggested as most likely cause. However, one should be careful about claiming a direct correlation. It remains important to exclude other causes, such as structural lesions, infections or subarachnoid hemorrhage, and future research is required to understand possible pathophysiological mechanisms and associations with the SARS-CoV-2 vaccine.

Keywords: COVID-19; Myoclonus; SARS-CoV-2; Thunderclap headache; Vaccine.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

References

    1. Romero-Sánchez CM, Díaz-Maroto I, Fernández-Díaz E, et al. Neurologic manifestations in hospitalized patients with COVID-19: The ALBACOVID registry. Neurology. 2020;95:e1060–e1070. doi: 10.1212/WNL.0000000000009937. - DOI - PMC - PubMed
    1. van der Meulen M, Kleineberg NN, Schreier DR, et al. COVID-19 and neurological training in Europe: from early challenges to future perspectives. Neurol Sci. 2020;41:3377–3379. doi: 10.1007/s10072-020-04723-9. - DOI - PMC - PubMed
    1. Patone M, Handunnetthi L, Saatci D, et al. Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med. 2021;27:2144–2153. doi: 10.1038/s41591-021-01556-7. - DOI - PMC - PubMed
    1. Polack FP, Thomas SJ, Kitchin N, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383:2603–2615. doi: 10.1056/nejmoa2034577. - DOI - PMC - PubMed
    1. Voysey M, Clemens SAC, Madhi SA, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2021;397:99–111. doi: 10.1016/S0140-6736(20)32661-1. - DOI - PMC - PubMed